These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24589363)

  • 1. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
    Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
    Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
    Brennan AT; Maskew M; Ive P; Shearer K; Long L; Sanne I; Fox MP
    J Int AIDS Soc; 2013 Nov; 16(1):18794. PubMed ID: 24256692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
    Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
    Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
    Bender MA; Kumarasamy N; Mayer KH; Wang B; Walensky RP; Flanigan T; Schackman BR; Scott CA; Lu Z; Freedberg KA
    Clin Infect Dis; 2010 Feb; 50(3):416-25. PubMed ID: 20043752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
    Wandeler G; Keiser O; Mulenga L; Hoffmann CJ; Wood R; Chaweza T; Brennan A; Prozesky H; Garone D; Giddy J; Chimbetete C; Boulle A; Egger M;
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):41-8. PubMed ID: 22743595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
    Shearer K; Fox MP; Maskew M; Berhanu R; Long L; Sanne I
    PLoS One; 2013; 8(8):e71719. PubMed ID: 23940782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
    Menezes CN; Duarte R; Dickens C; Dix-Peek T; Van Amsterdam D; John MA; Ive P; Maskew M; Macphail P; Fox MP; Raal F; Sanne I; Crowther NJ
    HIV Med; 2013 Apr; 14(4):217-25. PubMed ID: 23036096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
    Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
    AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
    Domingo P; Labarga P; Palacios R; Guerro MF; Terrón JA; Elías MJ; Santos J; Ruiz MI; Llibre JM;
    AIDS; 2004 Jul; 18(10):1475-8. PubMed ID: 15199328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes.
    Vinikoor MJ; Moyo C
    Trop Med Int Health; 2014 May; 19(5):499-500. PubMed ID: 24646005
    [No Abstract]   [Full Text] [Related]  

  • 15. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
    Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
    PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
    J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
    Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
    Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
    AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
    Rosen S; Long L; Fox M; Sanne I
    J Acquir Immune Defic Syndr; 2008 Jul; 48(3):334-44. PubMed ID: 18545151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.